Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
First Trust NASDAQ Pharmaceuticals ETF (FTXH) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
First Trust NASDAQ Pharmaceuticals ETF (FTXH) - free report >>
Image: Shutterstock
Pharma ETF (FTXH) Hits New 52-Week High
For investors seeking momentum, First Trust NASDAQ Pharmaceuticals ETF (FTXH - Free Report) is probably on the radar. The fund just hit a 52-week high and rose 37.2% from its 52-week low price of $23.29/share.
But, are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook to get a better idea of where it might head:
FTXH in Focus
The Nasdaq US Smart Pharmaceuticals Index is a modified factor weighted index, designed to provide exposure to US companies within the pharmaceuticals industry. The product charges 60 bps in annual fees (See: all healthcare ETFs here).
Why the Move?
The pharma market has regained momentum lately, driven by favorable regulatory developments and cheaper valuations. The Fed’s rate cuts have also improved funding conditions, and the increasing adoption of AI in U.S. healthcare continues to provide a meaningful tailwind for the sector.
More Gains Ahead?
Currently, FTXH has a Zacks ETF Rank #3 (Hold). However, it might continue its strong performance in the near term, with a positive weighted alpha of 21.53 (as per Barchart.com), which gives cues of a further rally.